All In Biotech

Drug Trial Radar · NCT01920061

A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)

A PHASE 1B OPEN-LABEL THREE-ARM MULTI-CENTER STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF PF-05212384 (PI3K/MTOR INHIBITOR) IN COMBINATION WITH OTHER ANTI-TUMOR AGENTS

Last checked: Nov 19, 2026Latest source record: Sep 13, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

110

Actual

Start

Sep 10, 2013

Primary completion

Jan 8, 2020

Study completion Jan 8, 2020

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Aug 9, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Basic science
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate PF-05212384 (gedatolisib) PI3K/mTOR inhibitor)) in combination with either docetaxel, cisplatin or dacomitinib in select advanced solid tumors. The study will assess the safety, pharmacokinetics and pharmacodynamics of these combinations in patients with advanced cancer in order to determine the maximum tolerated dose in each combination. The cisplatin combination expansion portion will evaluate the anti tumor activity of PF 05212384 plus cisplatin in patients with TNBC in 2 separate Arms (Arm 1 and Arm 2).

Conditions

  • Neoplasm

Interventions

  • PF-05212384 (gedatolisib)Drug

    PF-05212384 weekly intravenous infusions starting at 90 mg/wk as a 3 week cycle

  • DocetaxelDrug

    Docetaxel intravenous infusions once every 3 weeks starting at 75 mg/m\^2

  • CisplatinDrug

    Cisplatin intravenous infusions once every 3 weeks starting at 75 mg/m\^2

  • DacomitinibDrug

    Dacomitinib to be taken orally as a continuous once daily regimen at a starting dose of 30 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and CTime frame: Up to 21 days
  2. Percentage of Participants With Objective Response - Arm B ExpansionTime frame: Cycle 1 Day 1 up to 18 months

Locations

29 sites in 5 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Ronald Reagan UCLA Medical Center

    Los Angeles, California

  • UCLA Hematology Oncology

    Los Angeles, California

  • Westwood Bowyer Clinic

    Los Angeles, California

  • UCSF Helen Diller Family Comprehensive Cancer Center

    San Francisco, California

  • Santa Monica UCLA Medical Center & Orthopaedic Hospital

    Santa Monica, California

  • UCLA Hematology Oncology

    Santa Monica, California

  • University of Colorado Denver CTO (CTRC)

    Aurora, Colorado

  • University of Colorado Hospital

    Aurora, Colorado

  • Brigham and Women's Hospital

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Harper Professional Building

    Detroit, Michigan

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • Medical University of South Carolina/ University Hospital

    Charleston, South Carolina

  • Medical University of South Carolina

    Charleston, South Carolina

  • MUSC SCTR Research

    Charleston, South Carolina

  • MUSC Health East Cooper

    Mt. Pleasant, South Carolina

  • MUSC Specialty Care-North

    North Charleston, South Carolina

  • British Columbia Cancer Agency - Vancouver Centre

    Vancouver, British Columbia, Canada

  • Princess Margaret Cancer Center

    Toronto, Ontario, Canada

  • Istituto Europeo di Oncologia - Divisione Sviluppo di Nuovi Farmaci per Terapie Innovative

    Milan, MI, Italy

  • Istituto Regina Elena Struttura Complessa Oncologia Medica A

    Roma, RM, Italy

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Spain

  • University College London Hospital, NIHR UCLH Clinical Research Facility

    London, United Kingdom

  • Oxford Cancer Centre

    Oxford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.